Boston biotech takes aim at Gilead’s market: An HIV cure

Gilead largely dominates the HIV market, but Merck & Co. is pushing new products forward. Even as Merck is creating new treatment options for HIV patients, it is working with a Boston-based biotech on something even better: a cure.